Biology is ready.
Delivery is not.
Building the delivery infrastructure for biologics in skin.
Most systems optimize penetration. ExoGenis focuses on reproducibility.
A new category of controlled biologic delivery
Designed to deliver biologic formulations beyond the skin barrier with greater control, consistency, and workflow compatibility than conventional topical approach.
A clinic-friendly maintenance layer designed to support continuity between treatments without adding chair time.
How clinics use ExoGenis
Designed to integrate into existing treatments without disrupting workflow.
Professional treatment
Used after laser, RF, microneedling, or other dermatology procedures.
.svg)
.svg)
EXOGENIS BIOLOGIC DELIVERY PATCH
Controlled delivery into viable skin layers.
.svg)
CLINIC-GUIDED MAINTENANCE
Repeatable between-visit protocol guided by the clinic.
.svg)
Follow-Up
Supports continuity of care and treatment planning.
The missing layer between treatments
Bridging the gap between surface-level topicals and invasive injectables.
TOPICALS
Penetration-limited
Formulations largely remain on the surface with limited absorption and inconsistent bioavailability.
MICROINFUSION
Variable / manual
Delivery depends on technique and device, leading to variable depth, dose, and distribution across treatments.
EXOGENIS Delivery system
Controlled / repeatable
Precisely delivers the right formulation amount to the right layer, at the right time—consistently and reproducibly across every application.
INJECTIONS
Invasive / deeper
Bypasses natural skin architecture through invasive delivery, with higher variability and greater risk.
Clinical Impact
New Billable TREATMENT Step
- Add to existing treatments as an extra step
- No additional equipment required
- Protocol-based and easy to implement
Patient continuity
- Extends results between visits
- Encourages repeat appointments
- Supports structured care programs
"A simple protocol. Better results. More visits."
Designed for controlled use
.svg)
Safety
- No retained needles
- Controlled superficial interaction
.svg)
Validation
- Ex vivo skin interaction studies
- Ongoing evaluation
.svg)
Compatibility
- Designed for sensitive biologics
- Stable handling approach
Developed with clinical and technical partners
Innovationsfonden — non-dilutive funding for technology development
Sono-Tek — coating technology validation for biologic deposition
BioIVT — ex-vivo skin model testing for delivery performance
DTU — mechanical and release validation of microneedle system
Beyond Beta — accelerator support and early-stage validation
- OUR AMBITION
Become Denmark’s first dermatology-focused biologic delivery company, building the missing delivery layer between topicals and injections.
Interested in piloting ExoGenis?
We are looking for strategic partners in the professional skin care and dermatology space to join our exclusive pilot program.
Individual access coming soon.
Stay informed about our technology and future availability. Talk to us